The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
The United States Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for sonrotoclax, a next-generation investigational BCL2 inhibitor, for adult patients with
In this video interview, Hagop Kantarjian, MD, speaks with Michael Mauro, MD, leader of the CML program at Memorial Sloan Kettering Cancer Center,
Saad Usmani, MD, chief of the myeloma service and Eytan Stein, MD, chief of the leukemia service, both from Memorial Sloan Kettering Cancer
Attendees of SOHO 2025 will get a closer look at positive early safety and efficacy data for the novel Bruton’s tyrosine kinase (BTK)-targeted
With more than 10,500 global members, SOHO is poised to educate hematologic oncologists from every corridor of the Earth.
Death from chronic lymphocytic leukemia (CLL) in the U.S. has been declining, but disparities in outcomes persist, according to a population study of
The Society of Hematologic Oncology (SOHO) created the Young Investigator Program (YIP) to support the training and development of young investigators and to promote quality
The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to AK117 (ligufalimab) for the treatment of acute myeloid leukemia (AML).
The commercial launch of a new blood cancer test for patients with B- and T-cell lymphomas took place during the Thirteenth Annual Meeting
About 8% of patients with the slow-growing Waldenström macroglobulinemia (WM) died from cardiovascular diseases – not their cancer – between 1999-2000, raising questions
